Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNETISMM-32: elranatamab versus EPd, PVd, or Kd in relapsed/refractory multiple myeloma after prior anti-CD38 therapy
2023-507871-23-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- May 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of elranatamab in multiple myeloma (MM) (4 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Planned start May 2024; status: authorised.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-507871-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507871-23-00.